Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Alector

Alector

Alzheimer's Antibody Treatments

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

July 25, 2018
Alector raises a $133,000,000 series E round.
July 25, 2018
Alector raises a $133,000,000 series E round.
July 2018
Alector raises a $133,000,000 series E round from AbbVie Biotech Ventures, Amgen Ventures, Casdin Capital, Deerfield Management Company, Dementia Discovery Fund, Euclidean Capital, Federated Kaufmann Fund, Foresite Capital, Lilly Asia Ventures, Mission Bay Capital, New Leaf Venture Partners, OrbiMed, Perceptive Advisors, Polaris Partners and Section 32.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
July 30, 2021
FierceBiotech
Weeks after GlaxoSmithKline ponied up $700 million to work with Alector on a pair of "immuno-neurology" drugs, the neurodegenerative disease biotech pulled the curtain on early data showing its approach could slow the progression of an inherited form of dementia.
Alex Keown
July 6, 2021
BioSpace
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
Ben Adams
July 2, 2021
FierceBiotech
GlaxoSmithKline is penning an upfront and biobucks combo deal worth up to $2.2 billion with Fierce 15 winner Alector in neurodegenerative diseases.
Kate Goodwin
November 4, 2020
BioSpace
Both sides claim to be pleased with arbitration results in dispute over Prevail CEO's alleged breach of contract from time with Allector.

References

Golden logo
By using this site, you agree to our Terms & Conditions.